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Abstract 
Objectives: The effects of acute coronary syndrome (ACS) events on health-related quality of 
life (HRQoL) and the time dependency of these effects are unknown. This study aimed to 
characterise health utilities in ACS patients to aid development of future economic models 
estimating the cost per quality-adjusted life-year impact of ACS events and potential 
treatments. 
Methods: Multicentre, non-interventional, longitudinal evaluation of health utility in patients 
experiencing ACS or stroke events. EuroQol-5 dimension 3 level (EQ-5D-3L) surveys were sent 
to patients (≥18 years) from three UK centres 1 month after hospital discharge for myocardial 
infarction (MI), unstable angina (UA), or stroke. Patient demographics, lifestyle, and baseline 
utility score were collected in the first survey. Follow-up surveys were sent at 6, 12, 18, and 24 
months to prospectively capture utility and subsequent health events. Two methods of 
patient identification were adopted – prospective, where the patient’s qualifying event 
occurred after the study index date, and retrospective, where the patient’s qualifying event 
occurred prior to the study index date.  General healthy population utility values were 
assumed for pre-event HRQoL. 
Results: Between January 2011 and March 2014, 2,103 prospectively 
(n=1,350)/retrospectively (n=753) identified patients (mean age 68.3 years; 67.9% male) 
responded: MI 55.9% (n=1,176), UA 42.7% (n=898), stroke 1.4% (n=29); 24% had type 2 
diabetes. Post-event utility values were lower than general healthy population values, 
although significant differences in utility between subsequent 6 (n=1,031 change= -0.002), 12 
(n=1,096 change= -0.008), 18 (n=1,246 change= -0.007) and 24 (n=1,277 change= -0.004) 
month timepoints were not detected. Through multivariate regressions analyses, wheelchair 
use, current smoking, secondary mental and joint health events were associated with the 
greatest statistically significant utility decrements. 
Conclusions: This study indicates that health utility decreases following a CV event 
and,although some improvement occurs over the subsequent 24 months, general healthy 
population utility is not necessarily attained. 
KEYWORDS 
Acute coronary syndrome; Cardiovascular disease; Health utilities; Health-related quality of life  
SHORT TITLE 
PROSPECTIVE UTILITY STUDY OF MULTIPLE CV EVENTS  
Introduction 
Cardiovascular (CV) disease causes substantial morbidity and mortality worldwide, being the 
primary cause of non-communicable disease-related death in the USA and Europe [1–3]. 
Acute coronary syndrome (ACS) is an umbrella term for clinical conditions characterised by 
signs and symptoms of myocardial ischemia. ACS includes unstable angina (UA), ST segment 
elevation myocardial infarction (MI), and non-ST elevation MI, differentiated by ECG and 
biomarker (troponin) changes. Following an initial ACS event, the likelihood of a subsequent 
event, with its associated morbidity and mortality, increases [4,5]. Furthermore, such events 
are associated with more chronic conditions such as heart failure and strokes (REACH 
registry), long-term disability, and resulting costs to individual patients and society as a 
whole [6,7]. 
 
Patient-reported health status measures are often used as endpoints in clinical trials, 
although they are rarely used in the real-world setting [8]. As such, the published data often 
reflects a healthier clinical trial eligible patient cohort and does not reflect the real-world 
cohort fully. Furthermore, most published utilities represent post-event health states 
without distinguishing between the acute impact of the CV event and the chronic post-
event effects [9]. Consequently, the effects of initial and subsequent ACS events on health-
related quality of life (HRQoL) and the variables that may contribute to the magnitude of 
these effects are not well characterised or referenced. For health technology appraisal 
bodies in the UK, characterisation of health utilities in patients with ACS helps when 
estimating the economic impact of both ACS events and potential treatments to mitigate 
these events.  
 
The objectives of this study were to quantify: (1) The utility associated with a CV event; and 
(2) The change (decrement or increment) in utility associated with a CV event over a time 
frame of 24 months.   
 
  
Materials and methods 
Study design 
The study was a multicentre, non-interventional, longitudinal evaluation of health utility in 
patients who had experienced an ACS or stroke event. Patients were surveyed for a 
maximum of 2 years from their discharge date following their qualifying ACS or stroke 
event. The main study endpoint was health utility index value determined from the EuroQoL 
5-Dimensions 3 level Questionnaire (EQ-5D-3L).  
Setting 
Three National Health Service (NHS) trust hospitals (Barnet Hospital, Royal Free London NHS 
Foundation Trust; University Hospital of Wales, Cardiff and Vale University Health Board; 
and Peterborough City Hospital, Peterborough and Stamford Hospitals NHS Foundation 
Trust) with well-characterised CV patient populations participated in the study. In the 
national MINAP dataset of management of ACS patients, these centres were all normal or 
above normal in performance with evidence-based therapies. 
Patients 
Patients experiencing an ACS event or a stroke following an ACS event, were eligible for 
inclusion. Potential study participants were identified from participating site health records 
and, 1 month post discharge following a qualifying CV event (MI, UA, or stroke), were mailed 
an informed consent form and an initial study survey.  
Patients had to meet each of the following criteria to be considered eligible for inclusion in 
the study: age ≥18 years; experiencing a qualifying event of ACS (MI or UA) or stroke 
(defined as: stroke with a prior history of CV disease and with their most recent previous 
event prior to their qualifying stroke being an ACS event). Stroke and ACS patients were 
sought to understand the impact of stroke deliberately, particularly as ACS patients often do 
not survive a subsequent stroke event and therefore are unavailable usually to contribute. 
Patients were excluded if they met any of the following criteria: stroke but no history of CV 
disease; stroke and prior history of CV disease, but their most recent CV event was not an 
ACS event (i.e. stroke, stable angina, myocarditis etc…); prior diagnosis of type 1 diabetes 
mellitus; prior elective or emergency coronary revascularisation or coronary artery bypass 
graft surgery in the 6 weeks before their subsequent CV event. Patients who had undergone 
revascularisation more than 6 weeks before their CV event were assumed to have stabilised 
and were considered eligible for the study. 
Patients were identified by two methods; (1) prospectively, when the patient’s qualifying 
event occurred after the start of the study; or (2) retrospectively (Cardiff only) when the 
patient’s qualifying event had occurred before the start of the study. The inclusion of both 
prospectively and retrospectively identified patients enabled the collection of both early-
term and late-term time-dependent utility data from the start of the study. Inclusion of the 
retrospectively identified cohort also ensured adequate sampling of later timepoints, when 
patients in the prospectively identified group may have been lost to follow-up. 
Evaluations 
HRQoL was measured using the EuroQol five dimension – three level (EQ-5D-3L) outcome 
measure [10], a standardised measure of health status that has been validated in a wide 
range of health conditions and as a general population health measure in the UK and many 
other countries [11], and utilising the United Kingdom value set[12].  The visual analogue 
scale (VAS) part of the EQ-5D was not utilised as the study was designed to generate utility 
scores to inform economic models; as VAS scores are not used in this process they were 
deemed an unnecessary burden to the patients.  
The initial study survey included a demographic questionnaire; health status, as measured 
by the EQ-5D (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), 
and a question regarding current wheelchair use. Patients who provided signed informed 
consent and completed the initial survey were considered study responders. Study 
responders were mailed up to five surveys (one initial survey and four follow-up surveys at 
6, 12, 18, and 24 months after their qualifying event). The follow-up surveys consisted of the 
EQ-5D, the current wheelchair-use query, and two additional questions regarding the 
occurrence and type of any injury or illness that may have affected their health since they 
had completed the preceding study survey.  
The retrospectively identified patients were sent informed consent forms and surveys 
(initial and follow-up) consistent with the process established for the prospectively 
identified patients, except that that they could only receive a maximum of four surveys (at 
6-, 12-, 18-, and 24-month follow-ups) depending on the time elapsed since their qualifying 
CV event had occurred.  
Accrual period and sample size 
The study accrual period (identification of potential study subjects, informed consent form, 
and initial survey mailings) began in January 2011, following activation of the first study site 
on January 5, 2011, and continued until May 2012. Data collection continued until March 
2014 when the last follow-up patient questionnaire was returned. 
Data sources and measurement 
The majority of study variables were assessed by patient-completed questionnaires. The 
data captured included baseline characteristics, HRQoL, and the occurrence and type of 
secondary illness or injury affecting health between surveys. Patient questionnaires were 
anonymised: all included a unique identifier on each page that linked the questionnaire to 
each patient’s unique participant code. Type of qualifying event (MI, UA, or stroke) and 
subsequent in-hospital death during the study period were recorded by the site investigator 
based on institutional health records (it was not possible to capture deaths in the 
community, prior to study entry). 
At the Barnet and Peterborough study sites, questionnaire data and investigator-reported 
variables were entered into a Microsoft® Excel spreadsheet by investigator staff. To allow for 
interim data reviews and provide data back-ups, copies of the spreadsheets were regularly 
transferred from the study sites during the study period. Spreadsheet data were uploaded 
into a site-specific Microsoft Access database; surveys were mailed via commercial courier. 
Completed questionnaires from patients enrolled at the Cardiff study site were scanned into 
the site-specific Access database using optical character recognition software. Qualifying CV 
event type and death during the study period were recorded by investigator staff in a text 
file provided for uploading into the site-specific Access database linked to the scanned 
survey data. A separate study database was maintained for each study site; data from all 
sites were amalgamated only for study analyses.   Routine quality assurance checking was 
undertaken by two members of the analysis team. 
Sample size and statistical considerations 
It was determined that a population of 669 patients would be needed to attain a power of 
80% at a 5% α level to detect a difference in EQ-5D score of 0.03. A difference of 0.03 in EQ-
5D score is consistent with previously reported minimum clinically meaningful differences in 
health utility [13]. Loss to follow-up over the study duration was estimated to be 20% at 6 
months (i.e. the second survey) and maintained for the duration of the study. 
Baseline characteristics, qualifying event type, death (if noted in health records), and 
patient-reported causes of change in health during the study period were tabulated and 
analysed using simple summary statistics (proportions, means, standard deviations [SDs], 
and ranges). 
HRQoL was assessed using linear regression analysis to examine change in utility between 
timepoints and by multivariable linear regression analysis stratified by qualifying CV event 
and controlling for variables (i.e. age, sex, weight, type 2 diabetes mellitus [T2DM] status, 
smoking status, wheelchair use, and causes of changes in health) and interactions between 
variables. The calculated β, standard error, 95% confidence intervals, and p-values were 
tabulated, and the utility decrements associated with baseline characteristics and patient-
reported causes of change in health were calculated and presented by qualifying event. 
Regression analyses were conducted by patient group (prospectively identified patients, 
retrospectively identified patients, and combined patient groups) and survey time point.  
EQ-5D was used as the dependent variable with all other variables entered as independent 
variables.  Backward elimination stepwise regression models were utilised with non-
statistically significant variables removed one at a time; for consistency qualifying event, 
gender, age, and weight were forced variables entered into the model irrespective of their 
statistical significance. 
 
This study was approved by the National Institute for Social Care and Health Research 
(NISCHR) Research Ethics Service  (RES), Rec reference: 10/WSE03/37, IRAS project ID: 
61628. 
 
  
Results 
  
A total of 2,103 patients returned surveys; 1,350 (64.2%) prospectively identified patients 
and 753 (35.8%) retrospectively identified patients. Most patients in the prospective group 
were enrolled from Cardiff (48.4%) with Peterborough and Barnet recruiting 30.3% and 
21.3% of patients, respectively. Overall survey response rate at baseline was 62.0%, with 
follow-up response rates ranging 66.3% to 70.6% (Table 1). 
Baseline characteristics 
Baseline characteristics of the patient group by qualifying event are shown in Table 2. Of the 
2,103 patients enrolled, 1,176 (55.9%) had an MI, 898 (42.7%) had UA, and 29 (1.4%) had a 
stroke. Approximately one-quarter of patients had been diagnosed with type 2 diabetes 
mellitus at the time of completion of their initial survey (Table 2).  
Patients reported wheelchair use at baseline and at each follow-up survey. Wheelchair use 
was reported in 6.3% of patients at baseline and varied from 5.1% at Month 6 to 6.2% at 
Month 18 (Table 2).  
  
The majority of patients enrolled (86.9%) were not current smokers at the time of 
completing their initial study survey. Cardiff (12.6%) had the highest proportion of smokers 
followed by Peterborough (10.5%) and Barnet (6.3%). 
Outcomes 
Health utility: EQ-5D index scores 
As shown in Table 3, mean EQ-5D scores increased from baseline to Month 6, then 
subsequently decreased through Month 12 and Month 18, before increasing again at Month 
24.  
Mean EQ-5D scores was lowest in the stroke subgroup, ranging from 0.448 (SD 0.425) at 
Month 18 to 0.527 (SD 0.403) at Month 24. Mean EQ-5D was highest in the MI group, 
ranging from 0.690 (SD 0.290) at baseline to 0.708 (SD 0.322) at Month 18.  
Utility over time 
Table 4 shows changes in utility over time. Although decreases in utility were observed 
between each timepoint, none of these decreases were statistically significant (p=0.267 to 
0.785).    
Change in utility with secondary events 
The numbers of patients reporting an event that significantly affected their health, as 
assessed in each follow-up survey, are shown in Table 5. Joint and CV disease events were 
the most common event types influencing self-reported health. The ~12% of further CV 
events over the 24 months of follow up is consistent whatever the follow up duration 
available. This rate may be somewhat low for an average follow up of 24 months, compared 
to ACS registries such as GRACE [4].   
Changes in utility associated with baseline characteristics, wheelchair use, and secondary 
health events, as determined by multivariate regression analysis, are shown in Table 6. For 
discussion and presentation of regression model results, the initial survey was estimated to 
have been completed 1 month after the qualifying event.   
Baseline characteristics (e.g. qualifying event, gender ) were forced into the regression 
analysis model regardless of their significance to evaluate their effect over time. Changes in 
health due to secondary events were not included in the regression analysis model if they 
were not statistically significant. For example, cancer and complications of diabetes did not 
have a statistically significant effect on utility, most likely due to the small number of 
occurrences (cancer) or the effect on utility (complications of diabetes) not being 
significantly greater than already incurred by having the disease (baseline T2DM status).  
Adjusted EQ-5D scores over time for study participants whose qualifying event was an MI or 
UA are shown in Figure 1; stroke patients were excluded due to the small number of 
patients. The utility point estimated at months 6, 12, 18 and 24 are contrasted with mean 
utilities for individuals aged 68 years without complications derived from the English Health 
Survey [14].  
Male patients who experienced an MI had a mean utility score of 0.692 at Month 1 after the 
event and 0.649 at Month 6, before increasing to 0.727 at Month 12, 0.782 at Month 18, 
and 0.765 at Month 24 all lower than the general population mean of 0.886 (Figure 1). In 
patients with UA mean utility was 0.649 at Month 1 after the event decreasing to 0.614 at 
Month 6, before increasing to 0.688 at Month 12 and 0.761 at Month 18, before decreasing 
to 0.65 at Month 24; again, all lower than the general population mean. 
  
Discussion 
 
 
Several utility values are available to represent health states in patients with ACS [15]. 
However, many such values do not take into account the time between the CV event and 
the utility assessment. This limits interpretation of the impact of the event and the resulting 
quality of life implications, which can occur acutely and chronically following the event. In 
the current study, regression analyses indicated a modest increase utility from 1-month 
after the initial event (i.e. at initial survey completion) to month 24 months, although 
significant differences in utility were not detected between baseline and subsequent Month 
6, 18, 12, and 24 timepoints. It is noteworthy that health utility remained significantly lower 
than population norms for age-matched subjects without complications. Wheelchair use, 
current smoking, and secondary mental and joint health events were associated with the 
greatest utility decrements (>0.250 decrease). The effect of these baseline characteristics 
and secondary events were more profound than baseline T2DM status. The number of 
stroke patients enrolled in the study was inadequate for any conclusions to be made 
regarding this group.  
 
A potential limitation of the study was that CV history (aside from the qualifying event) was 
not available and that secondary or subsequent clinical events were captured via self-
reporting rather that via-health records.  Nevertheless, the high patient response to study 
surveys allowed for the collection of valuable utility information which could be examined in 
the context of initial CV events that characterised participants’ ACS.  In addition, the limited 
number of sites could introduce characteristic biases, such as the smoking rate differences 
seen. We have not looked for or adjusted for social class demographic differences between 
the sites, but these may be present given the average survival ages for the three regions is 
known to differ. Study patient death was likely underreported as only those deaths 
documented in hospital records were included. Furthermore, patients whose poor health or 
undocumented death precluded survey completion would have inappropriately biased 
results toward better utility. The study did not ask investigators to chase patient status if 
questionnaires were unreturned. 
 
Conclusion 
This real-world, survey based, study indicates that health utility decreases following a CV 
event, although some improvement occurs over the subsequent 24 months. If we assume a 
general population quality of life baseline from published data, this level of quality of life 
score is not approached by our study group as a whole.  
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Table 1. Survey response by time point 
  Patients Total 
Baseline 
Identified 
as eligible 
2,179 
Surveyed 2,179 
Responded 
1,350 
(62.0%) 
6 months 
Surveyed 2,096 
Responded 
1,389 
(66.3%) 
12 months 
Surveyed 2,287 
Responded 
1,597 
(69.8%) 
18 months 
Surveyed 2,386 
Responded 
1,685 
(70.6%) 
24 months 
Surveyed 2,536 
Responded 
1,732 
(68.3%) 
 
  
Table 2. Baseline patient characteristics  
 
 Survey post event Qualifying event 
Characteristic 1 month 6 months 12 months 18 months 24 months MI UA Stroke 
Combined n 1,350 1,298 1,473 1,508 1,539 1,176 898 29 
Mean age, years ± SD 
 (range) 
68.3 ± 12.3 
(24–97) 
69.0 ± 11.8 
(36-96) 
68.8 ± 11.9 
(26-97) 
68.8 ± 11.6 
(26-97) 
68.3 ± 11.5 
(34-96) 
67.4 ± 12.6 
(24–97) 
69.1 ± 11.9 
(31–97) 
75.9 ± 9.7 
(52–87) 
Male, n (%) 1,428 (67.9) 891 (68.6) 1,010 (68.6) 1,031 (68.4) 1,059 (68.8) 828 (70.4) 578 (64.4) 22 (75.9) 
Mean body weight, kg ± SD 
 (range) 
80.5 ± 17.3 
(29 – 200) 
80.5 ± 16.4 
(29 – 189) 
80.5 ± 17.2 
(39 – 200) 
80.5 ± 17.4 
(29 – 200) 
80.6 ± 17.0 
(39 – 200) 
79.8 ± 16.0 
(29 – 189) 
81.3 ± 19.0 
(45 – 200) 
83.3 ± 13.5 
(59 – 117) 
Smoking status, n (%) 
    Smoker 
    Non-smoker 
    Unknown 
 
151 (11.2) 
1,173 (86.9) 
26 (1.9) 
 
128 (9.9) 
1,162 (89.5) 
8 (0.6) 
 
143 (9.7) 
1,322 (89.7) 
9 (0.6) 
 
149 (9.9) 
1,352 (89.7) 
7 (0.5) 
 
151 (9.8) 
1,383 (89.9) 
5 (0.3) 
 
134 (11.4) 
1,031 (87.7) 
11 (0.9) 
 
99 (11.0) 
787 (87.6) 
12 (1.3) 
 
5 (17.2) 
21 (72.4) 
3 (10.3) 
Type 2 diabetes, n (%) 
     Yes 
     No 
     Unknown 
 
345 (25.6) 
979 (72.5) 
26 (1.9) 
 
328 (25.3) 
962 (74.1) 
7 (0.5) 
 
356 (24.2) 
1,108 (75.2) 
9 (0.6) 
 
362 (24.0) 
1,136 (75.3) 
10 (0.7) 
 
353 (22.9) 
1,171 (76.1) 
15 (1.0) 
 
345 (29.3) 
911 (77.5) 
20 (1.7) 
 
252 (28.1) 
628 (69.9) 
15 (1.7) 
 
7 (24.1) 
19 (65.5) 
6 (20.7) 
Wheelchair use, n (%) 85 (6.3) 66 (5.1) 84 (5.7) 94 (6.2) 87 (5.7) 55 (4.7) 59 (6.6) 5 (17.2) 
 
 MI, myocardial infarction; SD, standard deviation; UA, unstable angina. 
 
 
 
  
Table 3. Mean EQ-5D index scores 
Timepoint 
Mean (SD) 
EQ-5D score for 
all patients 
Mean (SD) EQ-5D score by qualifying event 
MI UA Stroke 
0 months 
 
n=1257 
0.659 (0.307) 
n=702 
0.690 (0.290) 
n=535 
0.623 (0.322) 
n=20 
0.496 (0.362) 
6 months 
 
n=1298 
0.672 (0.320) 
n=733 
0.702 (0.309) 
n=552 
0.637 (0.327) 
n=13 
0.525 (0.427) 
12 months 
 
n=1473 
0.669 (0.333) 
n=817 
0.708 (0.322) 
n=635 
0.625 (0.339) 
n=21 
0.498 (0.374) 
18 months 
 
n=1508 
0.659 (0.344) 
n=844 
0.692 (0.337) 
n=647 
0.622 (0.344) 
n=17 
0.448 (0.425) 
24 months 
 
n=1539 
0.665 (0.346) 
n=888 
0.706 (0.336) 
n=635 
0.611 (0.352) 
n=16 
0.527 (0.403) 
MI, myocardial infarction; UA, unstable angina. 
 
  
Table 4. Unadjusted change in EQ-5D score over time  
Time period 
(first – second 
timepoint) 
 
 
n 
 
Mean EQ-5D (SD) 
First timepoint 
 
Mean EQ-5D (SD) 
Second timepoint 
 
Change over 
time (SD) 
 
 
p-value 
0–6 months 1031 0.684 (0.288) 0.682 (0.316) –0.002 (0.237) 0.785 
6–12 months 1096 0.694 (0.307) 0.687 (0.326) –0.008 (0.225) 0.267 
12–18 months 1246 0.679 (0.329) 0.672 (0.341) –0.007 (0.226) 0.272 
18–24 months 1277 0.679 (0.336) 0.674 (0.346) –0.004 (0.222) 0.501 
0–24 months 920 0.690 (0.294) 0.684 (0.349) 0.005 (0.277) 0.551 
EQ-5D, EuroQoL 5-Dimensions questionnaire; SD, standard deviation. 
  
Table 5. Patients reporting secondary health events  
Secondary health event Month 6 Month 12 Month 18 Month 24 
Total No. responding 1,298 1,473 1,508 1,539 
Patients reporting event (%)     
CV disease 12.6 12.5 12.3 11.9 
Mental 1.9 2.6 2.7 3.1 
Eye/ear 4.2 5.9 5.8 5.5 
Respiratory 7.3 8.0 8.6 8.3 
Digestive 6.2 6.6 6.9 7.0 
Joint 21.9 26.1 29.1 29.7 
Injury 2.8 2.8 2.8 2.2 
Nervous 1.1 1.1 1.5 1.4 
Infection 5.8 5.8 6.8 6.6 
Cancer 3.3 2.3 3.2 3.4 
Diabetes complications 10.2 8.2 9.4 9.1 
Other 5.2 6.1 7.1 7.3 
CV, cardiovascular. 
 
 
 
  
Table 6. Adjusted EQ-5D utility scores  
 
Month 1a Month 6 Month 12 Month 18 Month 24 
EQ-5D 0.767 0.703 0.785 0.801 0.801 
Prospective – 0.143 0.088 0.055 0.073 
MI 0 – – – – 
Angina –0.043 –0.035 –0.039 –0.021b –0.047 
Stroke –0.136 –0.028b –0.197 –0.128b 0.026b 
Female –0.075 –0.054 –0.058 –0.019b –0.036 
Age –0.002 –0.003 –0.002 –0.001b –0.002 
Weight –0.002 –0.001 –0.001 –0.001b 0.000b 
Diabetes –0.106 –0.061 –0.072 –0.074 –0.063 
Smoker –0.149 –0.088 –0.109 –0.130 –0.116 
Wheelchair  –0.363 –0.236 –0.276 –0.285 –0.351 
CVD – –0.111 –0.113 –0.127 –0.090 
Mental – –0.291 –0.192 –0.226 –0.307 
Eye/ear – – – –0.115 – 
Respiratory – –0.174 –0.127 –0.064 – 
Digestive – –0.110 – – – 
Joint – –0.174 –0.215 –0.206 –0.230 
Injury – – –0.129 –0.108 – 
Nervous – – –0.218 –0.146 –0.161 
Infection – – – –0.092 –0.107 
Diabetes – – – – – 
Cancer – – – – – 
Other – –0.085 –0.073 –0.108 –0.112 
CVD, cardiovascular disease; EQ-5D, EuroQoL 5-Dimensions questionnaire; MI, myocardial 
infarction. 
aFor discussion and presentation of regression model results, the initial survey was 
estimated to have been completed 1 month after the qualifying event. 
bUtility decrement or increase not considered significant.  
Figure 
Figure 1. Adjusted EQ-5D by qualifying event over time. Note: Results of the English Health 
Survey (2003 publication) for individuals aged 68 years were used as a pre-event baseline. 
Initial survey completion estimated to have occurred 1 month after the qualifying event. EQ-
5D, EuroQoL 5-Dimensions questionnaire 
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